The Impact of Different Doses of Remifentanil on the Bispectral Index in Patients Undergoing Anesthesia with Remimazolam

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500103146

Enrollment

Unknown

Registered

2025-05-26

Start date

2025-05-30

Completion date

Unknown

Last updated

2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Test group 2 :Control infusion of 4 ng/ml remifentanil was given.

Test group 3 :Control infusion of 8 ng/ml remifentanil was given.

Test group 4 :Control infusion of 16 ng/ml remifentanil was given.

Control group :Control infusion of 0 ng/ml remifentanil was given.

Test group 1 :Control infusion of 2 ng/ml remifentanil was given.

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. elective operation. 2. ASA Physical Status Rating I or II. 3. Aged between 18 and 55 years old. 4. BMI:18~28kg/m^2.

Exclusion criteria

Exclusion criteria: 1. Patients undergoing cardiac or emergency surgery. 2. Severe liver and kidney dysfunction. 3. Patients with central nervous system disorders or with a history of long-term psychotropic drug use. 4. Allergic to benzodiazepines, opioids, propofol or muscle relaxants. 5. Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
bispectral index;	—

Secondary

Measure	Time frame
mean arterial pressure;heart rate;adverse events;	—

Countries

China

Contacts

Public ContactGuo Xiaowen

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)

guoxiaowen1315@hotmail.com+86 137 5712 3712

Outcome results